This bill would add a new section to Chapter 175H of the Massachusetts General Laws to authorize copay assistance programs for medications. It defines a copay assistance program as financial help that reduces patients’ out-of-pocket healthcare costs, and it allows manufacturers of both branded and generic medications to offer such programs to all Massachusetts residents, subject to federal law.
The bill requires manufacturers that offer these programs to notify the Department of Public Health and provide detailed descriptions and eligibility criteria. It also directs the department to make information about copay assistance programs readily available to the public and healthcare providers. In addition, the bill states that manufacturers of generic medications and their suppliers may not be fined or penalized for participating in a copay assistance program.
Impact
If enacted, the bill would create a new statutory framework governing medication copay assistance in Massachusetts by expressly permitting these programs and setting disclosure and access requirements. It would affect drug manufacturers, including both branded and generic manufacturers, as well as the Department of Public Health, which would take on an informational role. The bill would also protect generic manufacturers and their suppliers from fines or penalties related to participation in these programs, while preserving any limits required by federal law.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the measure appears to be framed as a consumer-access and affordability bill with a generally supportive policy posture. Its stated purpose is to help patients afford medications and improve transparency around available assistance programs. There is no recorded opposition in the provided materials, but the inclusion of federal-law limits and the specific treatment of generic manufacturers suggests the bill is designed to avoid conflicts with existing insurance and pharmaceutical rules.
Contention
The main potential points of contention are likely to involve how copay assistance interacts with insurance coverage rules, federal law, and pharmaceutical pricing practices. Insurers or pharmacy benefit managers could view broad availability of copay assistance as affecting cost-sharing structures, while manufacturers may focus on compliance burdens from the notification and disclosure requirements. Another possible issue is the bill’s explicit protection for generic manufacturers and their suppliers from fines or penalties, which may raise questions about how participation is regulated and whether branded and generic products are being treated differently.
Codifies child care copayments in law, expand zero copays to families under 125% FPL, lower costs for working families, and cap most copayments at 6% while preserving a 7% statutory maximum.